Chitin-glucan improves important pathophysiological features of irritable bowel syndrome

Figure 4 Improvement of clinical and histological scores in animals with colitis receiving chitin-glucan treatment. A: Stool consistency in mice with colitis [Dextran sodium sulfate (DSS), black] was improved by chitin glucan (CG) treatment at a concentration of 1.5 g/d (DSS + CG: 1.5 g, grey), or 3 g/d (DSS + CG: 3.0 g, white); B: Disease activity index (DAI) in mice with colitis (DSS, black) was improved by CG treatment at 1.5 g/d (DSS + CG: 1.5 g, grey), or 3.0 g/d (DSS + CG: 3.0 g, white); C: Regeneration score in mice with colitis (DSS-induced, black) was improved by CG treatment at 1.5 g/d (DSS + CG: 1.5 g, grey), or 3.0 g/d (DSS + CG: 3.0 g, white); D: Histologial score in mice with colitis (DSS, black) was improved by CG treatment at 1.5 g/d (DSS + CG: 1.5 g, grey), or 3.0 g/d (DSS + CG 3.0 g, white). ^aP < 0.05. DSS: Dextran sodium sulfate; CG: Chitin glucan; DAI: Disease activity index.